David T Coon, MD | |
1487 Belk Blvd, Oxford, MS 38655-5371 | |
(662) 234-1090 | |
(662) 234-0432 |
Full Name | David T Coon |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 1487 Belk Blvd, Oxford, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407962103 | NPI | - | NPPES |
00027799 | Medicaid | MS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 13516 (Mississippi) | Primary |
Mailing Address | Practice Location Address |
---|---|
David T Coon, MD 1487 Belk Blvd, Oxford, MS 38655-5371 Ph: (662) 234-1090 | David T Coon, MD 1487 Belk Blvd, Oxford, MS 38655-5371 Ph: (662) 234-1090 |
News Archive
An international team of researchers led by scientists from the University of the Witwatersrand's Evolutionary Studies Institute and the South African Centre for Excellence in PalaeoSciences today announced in two papers, published in the South African Journal of Science, the discovery of the most ancient evidence for cancer and bony tumours yet described in the human fossil record.
Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.
There is no syndrome that causes increased belly fat and decreased facial and limb fat among HIV-positive men who take antiretroviral drugs, according to a study by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.
› Verified 6 days ago
Eric Paul Dahl, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1487 Belk Blvd, Oxford, MS 38655 Phone: 662-234-1090 Fax: 662-234-0432 | |
Shavonne Bridgette Doyle, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2908 S Lamar Blvd Ste 100, Oxford, MS 38655 Phone: 662-281-0112 | |
Hunter Davis Haley, Family Medicine Medicare: Medicare Enrolled Practice Location: 497 Azalea Dr Ste 102, Oxford, MS 38655 Phone: 662-513-2000 | |
Willis N Dabbs, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1487 Belk Blvd, Oxford, MS 38655 Phone: 662-234-1090 Fax: 662-234-0432 | |
Ana-maria Nae Benefield, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1397 Belk Blvd, Oxford, MS 38655 Phone: 622-236-4675 | |
Shelly Renae-hughes Alamry, NP-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2706 W Oxford Loop Ste 103, Oxford, MS 38655 Phone: 662-380-5445 Fax: 662-580-5517 | |
Dr. Terri Jo Teague, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2173 S Lamar Blvd, Oxford, MS 38655 Phone: 662-234-6553 |